Skip to main content
. 2010 Feb;51(2):1198–1207. doi: 10.1167/iovs.09-4102

Figure 8.

Figure 8.

Analysis of levels of the caspase-3 substrate MEF2C after P-IQACRG administration. Rats received intravitreal injection of NMDA (45 nmol) plus glycine (10 nmol) along with the broad-spectrum caspase inhibitor zVAD-fmk (10 nmol), scrambled peptide, or P-IQACRG (150 pmol each). Vehicle injection (glycine alone) served as a control. Five hours after injection, retinas were harvested, and protein samples were subjected to Western blot analysis. (A) NMDA injection attenuated MEF2C protein levels in the retina. Simultaneous injection of zVAD blocked the NMDA-induced reduction in MEF2C. Equal loading was confirmed by the level of actin. (B) The decrease in MEF2C immunoreactivity after NMDA injection was largely prevented by P-IQACRG compared with scrambled peptide. (C) Densitometric analysis of MEF2C immunoreactivity allowed quantitative comparison of Western blot analysis with the mean value of vehicle-injected eyes set at 100%. Values are mean ± SEM (n = 4–7 for each group). Statistical significance was determined by one-way ANOVA followed by Fisher's PLSD multiple comparisons test.